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ABSTRACT. In the treatment of osteoporosis, the
tolerance of oral bisphosphonates is often low.
The high potency of ibandronate allows iv bolus
injections that can be repeated every 2 to 3
months. However, the best dose and time inter-
val of the treatment with iv ibandronate is still
debated. Efficacy of 2-mg ibandronate injected
every 3 months was tested in men with osteo-
porosis over 2 yr, in a prospective, open study.
Fourteen men with primary osteoporosis, mean
age 57±12 yr (range: 40-73), received 2-mg iban-
dronate iv every 3 months over 2 yr. All got 
1 g/day calcium and 880 UI/day vitamin D for 
2 yr. Bone mineral density (BMD) increased after
2 yr by 6.7±1.5% (mean change±SEM) at lumbar
spine (p<0.001), by 3.2±08% at trochanter
(p<0.001) and by 1.4±1.1% at femoral neck (ns).
Serum -crosslaps and osteocalcin decreased sig-
nificantly by 30-45 and 30%, respectively, during
the 2 yr of treatment. Serum calcium increased
from the lower to the middle tertile of the nor-
mal range during the 2 yr of the study. The ob-
served decrease of bone remodelling and the in-
crease of BMD are of the same magnitude as
those described with oral bisphosphonates. The
increase of plasma calcium confirms the positive
effect of the supplementation with calcium and
vitamin D. These results suggest that 3 months
are a good interval between two doses of iv iban-
dronate, when 2 mg are given.
(J. Endocrinol. Invest. 26: 728-732, 2003)
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INTRODUCTION
Osteoporosis is less common in men than in wom-
en, but approximately 25 to 30% of all hip fractures
occur in men, and many men have vertebral defor-
mities (1, 2). The causes of osteoporosis in men in-
clude excess of glucocorticoids, hypogonadism,
and a variety of other systemic conditions, medica-
tions and lifestyle factors; in about 50% there is no
obvious cause. Only few therapies have been eval-
uated in men. Testosterone therapy has limited ef-
ficacy in men with hypogonadism (3). Alendronate
significantly increased spine and hip bone mineral
density (BMD), and decreased the incidence of ver-
tebral fractures (4). However, bisphosphonates
cause gastrointestinal side effects in many patients
(5), and must be taken under strict conditions, which
affects compliance. These limitations led to the in-
vestigation of intermittent iv administration of
aminobisphosphonate, which showed an increase
in BMD of the spine and femoral neck after 3
monthly infusions of pamidronate and ibandronate
(6, 7). Ibandronate [1-hydroxy-3-(methylpenty-
lamino)-propylidene bisphosphonates] is a potent
aminobisphosphonate with proven efficacy in the
treatment of malignant hypercalcemia (8) and of
post-menopausal osteoporosis (9). For the treat-
ment of osteoporosis, iv ibandronate, 2 mg every
3 months as bolus injection, seems to be effective
(7). The goal of the present open pilot study was to
investigate the effect of 2 mg of ibandronate, ad-
ministered every 3 months over 2 yr, on BMD and
on biochemical markers of bone metabolism in men
with primary osteoporosis. 
MATERIALS AND METHODS
Study subjects
The patients (age 40 to 80 yr) were referred to the out-patient
clinic for osteoporosis at the University Hospital of Lausanne,
Switzerland. This pilot study was open and monocentric. The in-
clusion criteria were the presence of one osteoporosis fracture
(vertebra, femoral neck or wrist) and a BMD at the lumbar spine
of at least 1 SD below the Z-score, or at least 1.5 SD below the 
Z-score without any fracture. Men with secondary causes of os-
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teoporosis were ineligible, as were those with other bone dis-
eases, vitamin D deficiency, renal disease (indicated by a serum
creatinine concentration >160 mol/l), known endocrinopathy af-
fecting bone metabolism (hypogonadism, hyperparathyroidism,
hyperthyroidism, etc.), medication affecting bone metabolism
(corticosteroids or cyclosporine during the preceding 6 months;
calcitonin, fluor or bisphosphonates during the preceding 12
months), a history of cancer other than basal-cell carcinoma of
the skin, or a severe disability disease with a life expectancy of
less than 2 yr. All patients had given their written informed con-
sent prior to enrolment. The study was approved by the local
Ethics Committee.
Treatment
All patients included in this study received 2-mg ibandronate
every 3 months as a bolus injection at 0, 3, 6, 9, 12, 15, 18 and
21 months. All got oral supplementation with 1000-mg calcium
and 880-UI vitamin D every day during the 2 yr of treatment. 
Baseline and follow-up study
In the pre-treatment period, a complete history was obtained,
and each patient underwent a physical examination, electro-
cardiography, chest radiography, and serum parameters [os-
teocalcin, C-telopeptides, PTH, 25 (OH) vitamin D and 1,25
(OH) vitamin D, complete blood cell count, electrolytes, crea-
tinine, albumine, liver-function tests]. The patients included re-
turned for visits, biochemical measurements and treatment at 
0, 3, 6, 9, 12, 15, 18, 21 and 24 months. The BMD of the lum-
bar spine (anteroposterior view), femoral neck, trochanter and
distal forearm was measured by dual-energy X-ray absorp-
tiometry (Hologic QDR 2000) at baseline and at 6, 12, 18 and
24 months. Quality control of the BMD measurements, includ-
ing teaching of relevant technicians and phantom assessments,
was performed before and throughout the study by checking
accuracy and reproducibility on a daily basis. The precision of
our Hologic QDR 2000 equipment was 1.3% at the lumbar
spine, 1.8% at the femoral neck and 1.9% at the trochanter (7).
The precision was evaluated by repeated measurement in 10
subjects (4 measurements per subject) according to Gluer et
al. (10). The long-term stability was monitored during the study
by measuring an object of constant mass (European spine phan-
tom) on daily basis. The device showed a high stability during
all the study with an in vitro long-term reproducibility between
0.37 and 0.47% in BMD per year. All scans were reviewed by a
blinded expert, and reanalyzed upon request. BMD is ex-
pressed in grams of hydroxyapatite per cm2. Posteroanterior
and lateral radiographs of the lumbar and thoracic spine were
obtained at base line and after 2 yr of treatment. All radio-
graphs were reviewed by a blinded expert. 
Fasting serum samples were obtained in the morning for the
measurement of calcium corrected for albumine, phosphate,
creatinine, alkaline phosphatase, osteocalcin, -crosslaps, PTH.
Plasma 25 (OH) vitamin D, and 1,25 (OH) vitamin D were mea-
sured on fasting serum sample at baseline and at 12 months.
These parameters were determined by the following methods:
osteocalcin by a two-site radioimmunoassay as described by
Garnero et al. (11) (Elsa-Osteo, CIS bio international, Gif-sur-
Yvette, France; normal 9.6 to 26.8 ng/ml for men >30 yr); serum
-crosslaps by a two-site radioimmunoassay (Systèmes Elecsys
1010/1020, Roche Diagnostics, Meylan, France); intact PTH with
an immunoradiometric assay (Nichols Institute, San Juan
Capistrano, California; intact PTH 100T Kit; normal 10 to 
65 pg/ml); 25 (OH) vitamin D with a radioimmunoassay (DiaSorin,
Stillwater, Minnesota, normal 8.4 to 52.3 μg/l); 1,25 (OH) vita-
min D with a radioimmunoassay (Incstar corporation, Stillwater,
Minnesota). The correction of the serum calcium by albumine
(normal 2.1 to 2.5 mmol/l) was done according to statistics es-
tablished by the laboratory of the hospital (12): measured calci-
um - 0.012 [measured albumine - 39.5 (g/l)]. Safety parameters
measured included serum creatinine, sodium, potassium, ala-
nine aminotransferase, aspartate aminotransferase, gamma-GT
and complete blood count. All these latter determinations were
done by routine laboratory methods. 
Statistical analysis
The primary endpoint of the study was the lumbar spine BMD
and the secondary endpoint was the effects on osteocalcin and
-crosslaps. The analysis of BMD variables, osteocalcin and 
-crosslaps were based on the percent changes from baseline.
Statistical differences were evaluated by paired t-test. P values
<0.05 were considered to be significant.
RESULTS
Fourteen consecutive male patients with primary
osteoporosis were included in this study. Patient
characteristics at baseline are given in Table 1. At
entrance, 9 patients had experienced 18 vertebral
fractures and 4 non-vertebral fractures (wrist 3; up-
per arm 1). All these fractures occurred, either spon-
taneously or after a minor trauma. Nine patients
had a T-score below -2.5 DS either at the lumbar
spine or femoral neck. 
BMD
The BMD of the lumbar spine and of the trochanter
increased significantly by 6.7±1.5% and by
3.2±0.8% (percent change, mean±SEM) after 2 yr
of treatment (Fig. 1). The BMD of the femoral neck
and the total hip (Fig. 2) increased by 1.4±1.1% and
0.9±0.6%, respectively. The BMD of the distal fore-
arm increased by 1.5±0.5% (ns, data not shown). 
Biochemical markers
As shown in Figure 3, there was a progressive de-
crease in bone serum -crosslaps reaching a nadir
between 9 and 12 months, and a slight increase
Table 1 - Patient characteristics at baseline (mean±SEM)
Age 57±12 yr (range: 40-73 )
BMI 27±5 kg/m2
Fractures 9/14 patients
BMD lumbar spine -2.7±0.3 SD (T-score)
BMD femoral neck -2.3±0.8 SD (T-score)
BMI:body mass index; BMD: bone mineral density.
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during the second year of treatment at a level of
30% below the baseline. Osteocalcin decreased
slower and remained stable at 30 to 40% below the
baseline during the whole treatment. Corrected
serum calcium increased slightly from 2.11±0.08 to
2.24±0.09 mmol/l (p<0.01) during the 2 yr of treat-
ment. PTH, 25 (OH) vitamin D and 1,25 (OH) vita-
min D did not change during the 2 yr of the study. 
Fractures
Four fractures occurred in four men: 2 new sponta-
neous vertebral fractures in 2 men with pre-existent
vertebral fractures, and 2 traumatic fractures after a
fall in 2 men (radius, metacarpus). The treatment was
conservative in all cases.
Safety
There were no serious drug-related adverse events
and 38 non-serious adverse events during the
study. One patient dropped out after 1 yr and an-
other after 18 months for reasons not related to
ibandronate (one was depressed, one for unknown
reason). Flu-like symptoms were reported in 3 pa-
tients: in 2 patients after the first and second injec-
tion and in 1 after each injection. Flu-like symptoms
were controlled by self-administration of paraceta-
mol for 1 or 2 days, and were not a cause of 
withdrawal. One patient experienced a transient
skin rash 2 weeks after the last injection of iban-
dronate. The patient was examined by an allergol-
ogist, and no trigger was found. A transient rela-
tive eosinophilia occurred in one patient, and a
transient relative monocytosis in another patient,
without evident causes.
DISCUSSION
The patients included in this study had severe os-
teoporosis, considering the low BMD values and
the prevalence of pre-existing fractures in two
thirds of them (Table 1). Two-mg ibandronate 
given iv every 3 months for 2 yr increased BMD at
lumbar spine, trochanter and femoral neck. The
magnitude of this effect was similar to that report-
ed in men with osteoporosis after 2 yr of treatment
with 10-mg oral alendronate given daily: 6.7 vs
7.1% at the lumbar spine, 3.2 vs 4.3% at the
trochanter, and 1.4 vs 2.5% at the femoral neck (4).
These increases in BMD are also similar to those
reported in postmenopausal women with osteo-
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Fig. 1 - Mean (±SEM) percent changes from baseline in the bone
mineral density of the lumbar spine and the trochanter during 2 yr
of treatment with iv ibandronate. Asterisks indicate significant dif-
ferences from baseline (*p<0.05, **p<0.01, ***p<0.001).
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Fig. 2 - Mean (±SEM) percent changes from baseline in the
bone mineral density of the total hip and the femoral neck dur-
ing 2 yr of treatment with iv ibandronate. Asterisks indicate sig-
nificant differences from baseline (*p<0.05, **p<0.01).
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Fig. 3 - Mean (±SEM) percent changes from baseline in serum
osteocalcin and -crosslaps during 2 yr of treatment with iv iban-
dronate. Asterisks indicate significant differences from base line
(*p<0.05, **p<0.01, ***p<0.001).
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porosis after 2 yr of therapy with iv pamidronate
or oral alendronate or risedronate (6, 13, 14). 
Serum -crosslaps, a marker of bone resorption, de-
creased by 30 to 45%, and osteocalcin, a marker of
bone formation, by 30%; these values were ob-
tained 3 months after the last bolus of ibandronate,
just before the next injection. The magnitude of the
decline of the markers of bone remodelling was
slightly less pronounced to that published with bis-
phosphonates in men or in women (4, 6, 9, 13, 14).
In these studies, osteocalcin decreased by 35 to
40%, even by 50% (6, 13). The comparison with
markers of bone resorption is difficult. We used a
serum marker, while the above mentioned studies
used different urinary markers. The latter decreased
by 26 to 40% in some studies (6, 14), and by 50 to
74% in other studies (4, 9, 13). The pattern of the
decline of the markers was slightly different to that
described in other studies with bisphosphonates.
The maximum decrease was reached only after 9
to 12 months, while it is usually obtained already
after 3 to 6 months. However in women with os-
teoporosis, the injection of 2-mg ibandronate ev-
ery 3 months decreased osteocalcin progressively
with a nadir only after 9 months (7). In that study,
urinary C-telopeptide decreased by nearly 70% 1
month after the injection of 2-mg ibandronate, but
increased again at nearly 50% at 2 months. This in-
termittent decline of the resorption markers raises
the question if 3 months are an appropriate interval
between two iv doses of ibandronate. A significant
association between pharmacokinetics of oral iban-
dronate and clinical response in bone turnover and
bone mass in women with post-menopausal os-
teoporosis was shown (15). A recent preliminary re-
port confirms that, after 1 yr of treatment, the in-
crease of BMD and the suppression of bone mark-
ers achieved with 2-mg iv ibandronate given every
3 months in post-menopausal osteoporosis were
similar to those achieved with oral bisphosphonates
(16). These results suggest that 3 months are an ap-
propriate interval between two iv doses of iban-
dronate, when 2 mg are given.
The increase of the corrected serum calcium level
probably reflects the positive effect of supplemen-
tation with calcium and vitamin D. An immediate
and transient drop in serum calcium and rise in PTH
have been invariably found with iv bisphosphonates.
We could not observe such modifications, since the
measurements were repeated only after 3 months,
just before the next infusion of ibandronate. 
Flu-like symptoms were the only side effect reported.
They were well controlled with paracetamol, and
were not a cause of withdrawal. Flu-like symptoms
were described in approximately 20% of women with
osteoporosis treated with either 20-mg iv iban-
dronate, or a perfusion of 30-mg pamidronate (6, 7). 
Our study has several limitations: it is an uncontrolled
study, and the number of included patients was small.
In conclusion, this pilot study confirms that iv iban-
dronate is a promising treatment for osteoporosis in
men. The increases of BMD and the suppression of
bone markers achieved with 2 mg given every 3
months were similar to the results obtained with
oral bisphosphonates. The convenience of a bolus
injection every 3 months and the good tolerance
make this treatment a promising alternative to oral
bisphosphonates.
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